Arcutis Biotherapeutics, Inc. 8-K

What Happened

• Arcutis Biotherapeutics, Inc. filed an 8-K on June 9, 2026 reporting results of its 2026 Annual Meeting of Stockholders held for record holders as of April 8, 2026. All proposals were approved.
• Three Class III directors were elected to terms running until the 2029 annual meeting: Patrick J. Heron; Neha Krishnamohan; and Todd Franklin Watanabe. The Audit Committee’s selection of Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2026 was ratified. Stockholders also approved, on a non‑binding advisory basis, the compensation of the company’s named executive officers (say-on-pay).
• The Board approved revisions to the Amended and Restated Non-Employee Director Compensation Program, effective as of the Annual Meeting; the full text is filed as Exhibit 10.1 to the 8‑K.

Key Details

• Shares outstanding and entitled to vote as of record date: 125,073,249.
• Director election vote counts (votes for / votes withheld / broker non-votes):
  • Patrick J. Heron: 62,830,439 / 30,446,098 / 14,868,017.
  • Neha Krishnamohan: 74,956,903 / 18,319,634 / 14,868,017.
  • Todd F. Watanabe: 75,771,853 / 17,504,684 / 14,868,017.
• Auditor ratification (Ernst & Young LLP): 107,867,442 for, 15,748 against, 261,364 abstentions.
• Advisory vote on executive compensation: 88,728,269 for, 3,723,408 against, 824,860 abstentions; 14,868,017 broker non-votes.

Why It Matters

• Governance: The re-election of the three Class III directors and the ratification of EY maintain continuity in board oversight and financial reporting. While all nominees were elected, significant withheld votes on one nominee indicate some shareholder dissent worth monitoring.
• Compensation and costs: The Board’s approved revisions to non-employee director compensation may affect future cash and equity expenses and possible dilution; the full program text is available in Exhibit 10.1.
• Investor signal: The strong advisory approval of executive pay (say-on-pay) suggests broad investor support, though a measurable minority opposed — a detail investors and governance-focused shareholders may watch going forward.